# Amyloidosis: Diagnosis, Treatment, Outcomes

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the molecular mechanisms, diagnosis, treatment, and prognosis of amyloidosis, with a particular emphasis on transthyretin-related cardiac and familial amyloid polyneuropathy. It covers topics such as RNAi therapy, cardiovascular magnetic resonance, and immunoglobulin light chain involvement. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t11305 |
| Works | 173 |

## Topic papers all

Showing 15 of 173.

- [Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis](https://scholariq.org/papers/patisiran-an-rnai-therapeutic-for-hereditary-transthyretin-amyloidosis/)
- [Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy](https://scholariq.org/papers/tafamidis-treatment-for-patients-with-transthyretin-amyloid-cardiomyopathy/)
- [Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease](https://scholariq.org/papers/secreted-amyloid-protein-similar-to-that-in-the-senile-plaques-of-alzheimer-s/)
- [M-Type Phospholipase A <sub>2</sub> Receptor as Target Antigen in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/m-type-phospholipase-a-sub-2-sub-receptor-as-target-antigen-in-idiopathic/)
- [International Consensus Diagnostic Criteria for Autoimmune Pancreatitis](https://scholariq.org/papers/international-consensus-diagnostic-criteria-for-autoimmune-pancreatitis/)
- [A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid](https://scholariq.org/papers/a-pathogenic-mutation-for-probable-alzheimer-s-disease-in-the-app-gene-at-the-n/)
- [International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology](https://scholariq.org/papers/international-standardization-of-criteria-for-the-histologic-diagnosis-of-renal/)
- [Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis](https://scholariq.org/papers/definition-of-organ-involvement-and-treatment-response-in-immunoglobulin-light/)
- [APOE and Alzheimer disease: a major gene with semi-dominant inheritance](https://scholariq.org/papers/apoe-and-alzheimer-disease-a-major-gene-with-semi-dominant-inheritance/)
- [C3 glomerulopathy: consensus report](https://scholariq.org/papers/c3-glomerulopathy-consensus-report/)
- [Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/expert-consensus-recommendations-for-the-suspicion-and-diagnosis-of/)
- [The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group](https://scholariq.org/papers/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report/)
- [Genotype and Phenotype of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/genotype-and-phenotype-of-transthyretin-cardiac-amyloidosis/)
- [High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis](https://scholariq.org/papers/high-dose-melphalan-versus-melphalan-plus-dexamethasone-for-al-amyloidosis/)
- [CMR Imaging Predicts Death and Other Adverse Events in Suspected Cardiac Sarcoidosis](https://scholariq.org/papers/cmr-imaging-predicts-death-and-other-adverse-events-in-suspected-cardiac/)

## Topic primary papers

Showing 15 of 60.

- [Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis](https://scholariq.org/papers/patisiran-an-rnai-therapeutic-for-hereditary-transthyretin-amyloidosis/)
- [Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy](https://scholariq.org/papers/tafamidis-treatment-for-patients-with-transthyretin-amyloid-cardiomyopathy/)
- [Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis](https://scholariq.org/papers/definition-of-organ-involvement-and-treatment-response-in-immunoglobulin-light/)
- [Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/expert-consensus-recommendations-for-the-suspicion-and-diagnosis-of/)
- [The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group](https://scholariq.org/papers/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report/)
- [Genotype and Phenotype of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/genotype-and-phenotype-of-transthyretin-cardiac-amyloidosis/)
- [High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis](https://scholariq.org/papers/high-dose-melphalan-versus-melphalan-plus-dexamethasone-for-al-amyloidosis/)
- [Diagnosis of monoclonal gammopathy of renal significance](https://scholariq.org/papers/diagnosis-of-monoclonal-gammopathy-of-renal-significance/)
- [Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy](https://scholariq.org/papers/vutrisiran-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy/)
- [Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis](https://scholariq.org/papers/prevalence-and-outcomes-of-concomitant-aortic-stenosis-and-cardiac-amyloidosis/)
- [Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice](https://scholariq.org/papers/screening-for-transthyretin-amyloid-cardiomyopathy-in-everyday-practice/)
- [Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/patisiran-treatment-in-patients-with-transthyretin-cardiac-amyloidosis/)
- [Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients](https://scholariq.org/papers/outcome-of-al-amyloidosis-after-high-dose-melphalan-and-autologous-stem-cell/)
- [Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy](https://scholariq.org/papers/transthyretin-stabilization-by-ag10-in-symptomatic-transthyretin-amyloid/)
- [Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy](https://scholariq.org/papers/cost-effectiveness-of-tafamidis-therapy-for-transthyretin-amyloid-cardiomyopathy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.